Literature DB >> 16567835

Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography.

Christoph H Saely1, Lorena Koch, Fabian Schmid, Thomas Marte, Stefan Aczel, Peter Langer, Guenter Hoefle, Heinz Drexel.   

Abstract

OBJECTIVE: The International Diabetes Federation (IDF) has recently established a worldwide consensus definition of the metabolic syndrome. No prospective data are available on the cardiovascular risk associated with this new metabolic syndrome definition. RESEARCH DESIGN AND METHODS: In a prospective study of 750 coronary patients, we recorded vascular events over 4 years.
RESULTS: From our patients, 37.3% (n = 280) had the metabolic syndrome according to the Adult Treatment Panel III (ATPIII) definition and 45.5% (n = 341) according to the IDF definition. The metabolic syndrome as defined by the ATPIII criteria significantly predicted vascular events (adjusted hazard ratio 1.745 [95% CI 1.255-2.427]; P = 0.001), but the metabolic syndrome as defined by IDF criteria did not (1.189 [0.859-1.646]; P = 0.297). Accordingly, event-free survival was significantly lower among patients who fulfilled the ATPIII but not the IDF criteria than among those who met the IDF but not the ATPIII criteria (P = 0.012). The metabolic syndrome as defined by ATPIII criteria remained significantly predictive of vascular events after adjustment for type 2 diabetes but not after additional adjustment for the metabolic syndrome components high triglycerides and low HDL cholesterol. These lipid traits in turn proved significantly predictive of vascular events even after adjustment for the metabolic syndrome.
CONCLUSIONS: The ATPIII definition of the metabolic syndrome confers a significantly higher risk of vascular events than the IDF definition. However, among angiographied coronary patients, even the ATPIII definition of the metabolic syndrome does not provide prognostic information beyond its dyslipidemic features.

Entities:  

Mesh:

Year:  2006        PMID: 16567835     DOI: 10.2337/diacare.29.04.06.dc05-2011

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Authors:  Fabrice M A C Martens; Frank L J Visseren
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 4.810

2.  Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome.

Authors:  Elisabeth Wehr; Reinhard Möller; Renate Horejsi; Albrecht Giuliani; Daisy Kopera; Natascha Schweighofer; Andrea Groselj-Strele; Thomas R Pieber; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Todd M Brown; Jenifer H Voeks; Vera Bittner; Monika M Safford
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

4.  The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Mona Alidadi; Amirhossein Sahebkar; Saeid Eslami; Farveh Vakilian; Lida Jarahi; Maryam Alinezhad-Namaghi; Seyed Mostafa Arabi; Saba Vakili; Fariba Tohidinezhad; Yasaman Nikooiyan; Abdolreza Norouzy
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.

Authors:  Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.554

6.  Low bone mineral density is not associated with angiographically determined coronary atherosclerosis in men.

Authors:  S Beer; C H Saely; G Hoefle; P Rein; A Vonbank; J Breuss; B Gaensbacher; A Muendlein; H Drexel
Journal:  Osteoporos Int       Date:  2009-11-21       Impact factor: 4.507

7.  Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?

Authors:  Todd M Brown; Dhananjay Vaidya; William J Rogers; David D Waters; Barbara V Howard; Jean-Claude Tardif; Vera Bittner
Journal:  J Womens Health (Larchmt)       Date:  2008-06       Impact factor: 2.681

8.  An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population.

Authors:  D F Waterhouse; A M McLaughlin; F Sheehan; D O'Shea
Journal:  Ir J Med Sci       Date:  2009-01-08       Impact factor: 1.568

9.  National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease?

Authors:  Abbas Rezaianzadeh; Seyedeh-Mahdieh Namayandeh; Seyed-Mahmood Sadr
Journal:  Int J Prev Med       Date:  2012-08

10.  Cardio-metabolic features of type 2 diabetes subjects discordant in the diagnosis of metabolic syndrome.

Authors:  Sa Rah Lee; Ying Han; Ja Won Kim; Ja Young Park; Ji Min Kim; Sunghwan Suh; Mi-Kyoung Park; Hye-Jeong Lee; Duk Kyu Kim
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.